C/M@Alb NCs unveiled synergistic in vivo therapeutic efficacy against various tumors such as HT-29 subcutaneous colorectal tumors, E0771 orthotopic murine breast tumors, and patient-derived lung tumors, indicating a potential nanotherapeutic agent for the treatment of several types of cancers in the clinic. This evidence concerns the gene ALB and breast neoplasm.